Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)
China · Delayed Price · Currency is CNY 25.56
-0.03 (-0.12%)
Jun 11, 2026, 2:05 PM CST
SHA:603351 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,332 | 1,325 | 1,287 | 1,152 | 1,103 | 1,032 |
Other Revenue | 9.81 | 9.81 | 9.94 | 4.21 | 8.36 | 10.24 |
| 1,342 | 1,335 | 1,297 | 1,156 | 1,111 | 1,042 | |
Revenue Growth (YoY) | 1.90% | 2.95% | 12.19% | 4.04% | 6.59% | 41.60% |
Cost of Revenue | 960.8 | 961.07 | 938.49 | 842.97 | 810.66 | 762.68 |
Gross Profit | 380.81 | 373.97 | 358.26 | 312.87 | 300.36 | 279.63 |
Selling, General & Admin | 115.68 | 113.9 | 115.84 | 121.5 | 126.32 | 107.53 |
Research & Development | 82.43 | 81.53 | 71.56 | 55.64 | 53.87 | 40.73 |
Other Operating Expenses | 0.97 | 1.29 | 1.25 | 3.23 | 7.6 | 6.77 |
Operating Expenses | 200.1 | 197.08 | 188.99 | 180.67 | 183.31 | 157.17 |
Operating Income | 180.72 | 176.89 | 169.27 | 132.2 | 117.04 | 122.46 |
Interest Expense | -11.61 | -10.68 | -13.84 | -15.25 | -12.48 | -7.04 |
Interest & Investment Income | 0.5 | 0.53 | 0.93 | 0.78 | 0.63 | 1.47 |
Currency Exchange Gain (Loss) | -1.2 | -1.2 | 1.54 | 0.53 | 2.48 | -0.51 |
Other Non Operating Income (Expenses) | -2.01 | -0.12 | -0.48 | -0.03 | -0.2 | -0.71 |
EBT Excluding Unusual Items | 166.39 | 165.41 | 157.42 | 118.23 | 107.47 | 115.67 |
Gain (Loss) on Sale of Investments | 3.41 | 3.41 | 12 | 1.44 | -0.11 | 1.7 |
Gain (Loss) on Sale of Assets | -0.41 | -0.41 | -0.17 | -0.18 | -0.1 | -0.18 |
Other Unusual Items | 4.22 | 4.23 | 2.87 | 1.95 | 5.59 | 1.54 |
Pretax Income | 173.62 | 172.64 | 172.13 | 121.44 | 112.85 | 118.74 |
Income Tax Expense | 23.55 | 23.66 | 26.93 | 12.33 | 18.42 | 18.59 |
Earnings From Continuing Operations | 150.07 | 148.99 | 145.21 | 109.11 | 94.43 | 100.15 |
Net Income to Company | 150.07 | 148.99 | 145.21 | 109.11 | 94.43 | 100.15 |
Minority Interest in Earnings | 1.95 | 1.98 | 1.22 | 3.08 | 0.6 | 1.22 |
Net Income | 152.02 | 150.97 | 146.42 | 112.2 | 95.03 | 101.37 |
Net Income to Common | 152.02 | 150.97 | 146.42 | 112.2 | 95.03 | 101.37 |
Net Income Growth | 2.43% | 3.11% | 30.50% | 18.07% | -6.26% | 0.92% |
Shares Outstanding (Basic) | 136 | 136 | 136 | 135 | 132 | 133 |
Shares Outstanding (Diluted) | 136 | 136 | 136 | 135 | 134 | 133 |
Shares Change (YoY) | -0.33% | 0.32% | 0.29% | 1.00% | 0.35% | 2.25% |
EPS (Basic) | 1.12 | 1.11 | 1.08 | 0.83 | 0.72 | 0.76 |
EPS (Diluted) | 1.12 | 1.11 | 1.08 | 0.83 | 0.71 | 0.76 |
EPS Growth | 2.77% | 2.78% | 30.12% | 16.90% | -6.58% | -1.30% |
Free Cash Flow | 186.85 | 186.07 | 170.34 | 47.17 | -124.91 | -247.16 |
Free Cash Flow Per Share | 1.38 | 1.37 | 1.26 | 0.35 | -0.93 | -1.85 |
Dividend Per Share | 0.600 | 0.600 | 0.400 | 0.300 | 0.280 | 0.300 |
Dividend Growth | 50.00% | 50.00% | 33.33% | 7.14% | -6.67% | - |
Gross Margin | 28.38% | 28.01% | 27.63% | 27.07% | 27.03% | 26.83% |
Operating Margin | 13.47% | 13.25% | 13.05% | 11.44% | 10.54% | 11.75% |
Profit Margin | 11.33% | 11.31% | 11.29% | 9.71% | 8.55% | 9.73% |
Free Cash Flow Margin | 13.93% | 13.94% | 13.14% | 4.08% | -11.24% | -23.71% |
EBITDA | 307.31 | 299.64 | 276.64 | 200.26 | 180.62 | 162.12 |
EBITDA Margin | 22.91% | 22.44% | 21.33% | 17.33% | 16.26% | 15.55% |
D&A For EBITDA | 126.6 | 122.75 | 107.37 | 68.06 | 63.58 | 39.66 |
EBIT | 180.72 | 176.89 | 169.27 | 132.2 | 117.04 | 122.46 |
EBIT Margin | 13.47% | 13.25% | 13.05% | 11.44% | 10.54% | 11.75% |
Effective Tax Rate | 13.56% | 13.70% | 15.64% | 10.15% | 16.32% | 15.65% |
Revenue as Reported | 1,342 | 1,335 | 1,297 | 1,156 | 1,111 | 1,042 |
Advertising Expenses | - | 1.2 | 1.09 | 1.82 | 0.39 | 0.61 |